BackG&E Herbal Biotechnology , Ltd. Overview

G&E Herbal Biotechnology , Ltd. Current Cash

Track G&E Herbal Biotechnology , Ltd.'s current cash ($46M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$46.46M
↓ 22.01% YoYΔ $-13.11M vs prior year quarter

Peer trimmed avg / median

Loading

G&E Herbal Biotechnology , Ltd. Current Cash History

Loading

G&E Herbal Biotechnology , Ltd. vs. peers: Current Cash Comparison

Loading

G&E Herbal Biotechnology , Ltd. Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

G&E Herbal Biotechnology , Ltd. (4911.TWO) FAQ

G&E Herbal Biotechnology , Ltd. posts a current cash of $46M as of September 2026. That compares with $60M in the prior-year period — down 22.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, G&E Herbal Biotechnology , Ltd.'s current cash was $60M. The latest reading is $46M — a 22.0% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of G&E Herbal Biotechnology , Ltd.'s financial statement story. At $46M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 4911.TWO's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; G&E Herbal Biotechnology , Ltd.'s other metric pages and overview cover the third.

Judging G&E Herbal Biotechnology , Ltd. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current cash easier to interpret. Start with $46M here, then scan peer and history charts to see if the gap is persistent.